ARGX-113-2004: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluatethe Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With PrimaryImmune Thrombocytopenia

Project: Research project

Project Details

Description

ARGX-113-2004: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
StatusActive
Effective start/end date2/15/212/28/26

Funding

  • Argenx

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.